BNP Paribas Financial Markets
RGC icon

BNP Paribas Financial Markets’s Regencell Bioscience RGC Stock Holding History

BNP Paribas Financial Markets’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18 Buy
+3
New +$72 ﹤0.01% 5855
2025
Q4 		– Sell
-4,682
Closed -$72.3K – 5917
2025
Q3 		$72.3K Sell
4,682
-40,368
-90% -$579K ﹤0.01% 4437
2025
Q2 		$768K Buy
+45,050
New +$549K ﹤0.01% 3075

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Amundi
Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

BNP Paribas Financial Markets's RGC Position: Q2 2026 in Review

BNP Paribas Financial Markets opened a new position in Regencell Bioscience (RGC) in Q2 2026: 3 shares worth $18. The stake represents ﹤0.01% of the portfolio and ranks #5855 among its holdings. This is a return to the name: BNP Paribas Financial Markets previously reported a position in RGC as recently as Q3 2025.

BNP Paribas Financial Markets first reported a position in RGC in Q2 2025 and has held it in 3 quarters since. The position peaked at $768K in Q2 2025. 35 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

  • BNP Paribas Financial Markets held 3 shares of Regencell Bioscience worth $18 as of Q2 2026.
  • Regencell Bioscience was a new BNP Paribas Financial Markets position in Q2 2026.
  • Regencell Bioscience made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5855 holding.
  • BNP Paribas Financial Markets first reported a position in Regencell Bioscience in Q2 2025 and has held it in 3 quarters since.
  • BNP Paribas Financial Markets's Regencell Bioscience position peaked at $768K in Q2 2025.
  • 35 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.